Floxuridine

Category	Cytomegalovirus (CMV)
CAS	50-91-9
Description	Floxuridine is an antineoplastic antimetabolite, used in the treatment of colon carcinoma and colorectal cancer that has metastasized to the liver.

Quotation Now

Product Information

Synonyms	Deoxyfluorouridine; FDUR; NSC 27640; NSC27640; NSC-27640; 2'-Deoxy-5-fluorouridine; 1-(2-Deoxy-β-D-ribofuranosyl)-5-fluorouracil; 5-Fluoro-2'-deoxy-uridine; 5-Fluorodeoxyuridine; 5-Fluorouracil 2'-Deoxyriboside; FdUrd
IUPAC Name	5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
Molecular Weight	246.19
Molecular Formula	C9H11FN2O5
Canonical SMILES	C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O
InChI	InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
InChIKey	ODKNJVUHOIMIIZ-RRKCRQDMSA-N
Boiling Point	483.0±55.0 °C at 760 mmHg
Melting Point	135-145°C
Flash Point	245.9±31.5 °C
Purity	≥95%
Density	1.64 g/cm3
Solubility	Soluble in DMSO (Slightly), Methanol (Slightly), Water (Sparingly)
Appearance	White to Off-White Solid
Storage	Store at -20°C
Complexity	386
Exact Mass	246.06519962
Index Of Refraction	1.676
In Vitro	Floxuridine (0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells. Floxuridine (300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways. Floxuridine (0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M. Floxuridine is against Mueller Hinton Broth and Tryptic Soy Broth with MIC values of 0.25 μM and 0.81 μM, respectively. It also reported to be a very potent inhibitor of staphylococcal growth (MIC, 0.025-0.00313 μM).
In Vivo	Floxuridine (intraperitoneal injection; 0.5-1.25 mg/kg; once per day for 7 days or single dose) is sufficient to show statistically significant protection against S. aureus infection at 0.5 mg/kg for 7 days. In addition, 1.25 mg/kg single administration of the compound shows statistically significant protection against S. aureus infection.
PSA	104.55000
Target	Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; Bacterial; CMV; HSV;
Vapor Pressure	0.0±2.8 mmHg at 25°C
XLogP3-AA	-1.2